• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Success Sans Side Effects

Article

Paris - Polypodium leucotomos extract (PLE) is an effective systemic chemoprotective that can be used for controlling and inhibiting ultraviolet radiation (UVR)-induced harmful changes in the skin, including PUVA-induced phototoxicity reactions, Salvador Gonzalez, M.D., Ph.D., reported at the World Congress of Dermatology.

Recent Videos
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
Related Content
Expert Reflections: Impact of Dermatology Times

Expert Reflections: Impact of Dermatology Times

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita

Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita

Article
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD

The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD

Podcast
First Study Reveals Covariate-Adjusted Effects of New Actinic Keratosis Therapies for Face and Scalp

First Study Reveals Covariate-Adjusted Effects of New Actinic Keratosis Therapies for Face and Scalp

Article
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS

Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS

Article
© 2024 MJH Life Sciences

All rights reserved.